A5102006443- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Venous Thromboembolism Diagnosis and Management
- Blood Coagulation and Thrombosis Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Eosinophilic Esophagitis
- Breast Lesions and Carcinomas
- Urinary Tract Infections Management
- Acute Lymphoblastic Leukemia research
- Renal Transplantation Outcomes and Treatments
- Healthcare Systems and Technology
- Atrial Fibrillation Management and Outcomes
- Acute Myeloid Leukemia Research
- Estrogen and related hormone effects
- Advanced Neuroimaging Techniques and Applications
- Vascular Tumors and Angiosarcomas
Luigi Sacco Hospital
2020
University of Rome Tor Vergata
2018
Ospedale Civile di Venezia
2014-2015
Fondazione Piemontese per la Ricerca sul Cancro Onlus
2011-2013
Ospedale San Paolo
2013
Candiolo Cancer Institute
2011-2012
Weatherford College
2011
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2005-2009
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2003-2004
New York University
1998
Abstract Background. Human epidermal growth factor receptor (HER)-2 testing in patients with operable breast cancer is aimed at identifying candidates for adjuvant anti–HER-2 treatment. However, commonly defined “HER-2−” tumors express variable levels of the HER-2 protein, which can influence prognosis. We compared clinical outcomes stratified according to a common algorithm. Methods. studied 1,150 women (median age, 58 years; range, 22–94 years) undergoing surgery early our institution....
The relationship between quantitative immunohistochemical hormone receptor expression and response to the combination of trastuzumab with chemotherapy in HER2-positive advanced breast cancer is currently unknown.Estrogen (ER) progesterone was studied both as a dichotomous variable (positivity set at ≥ 1% positive cells) continuous variable. effect on overall rate progression-free survival patients receiving trastuzumab-based treatment by univariate multivariate analysis.One hundred eleven...
In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2‐targeting agents without chemotherapy (CT) in HER2‐positive metastatic breast cancer (MBC) patients. The primary tumors patients enrolled this study offered unique opportunity identify biomarkers that could predict durable clinical benefit from CT‐free anti‐HER2 therapy. Patients with MBC were trastuzumab or lapatinib as first‐line CT added therapy failing achieve tumor regression at...
Abstract Background. We evaluated the patterns of care and clinical outcomes metastatic breast cancer patients treated with first-line trastuzumab-based therapy after previous (neo)adjuvant trastuzumab. Materials Methods. A total 416 consecutive, HER2-positive who had received were identified at 14 Italian centers. 113 presented de novo stage IV disease analyzed separately. Dichotomous using logistic regression time-to-event Cox proportional hazards models. Results. In 202 trastuzumab-naïve...
The San Antonio Breast Cancer Symposium is considered by researchers and physicians involved in breast cancer management as one of the most important international events on subject. A dense program plenary presentations novel findings, main lectures, poster discussions displays, it encompasses all aspects rapidly evolving field research treatment. This article briefly summarises some that are expected to have an impact medical treatment cancer.
Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week a 12-week response-oriented schedule, targeting complete clinical and haematological remission (CR). CR achieved 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement 5/17 without, P = 0.006), most after 2 weeks of 100 imatinib. The maximum dose had no effect early unresponsive patients. Low-dose, short-course represent rational...
Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive treated from March 2007 to December 2013 were collected 13 Italian institutions. Estimates progression-free survival (PFS) overall (OS) obtained the Kaplan-Meier method compared logrank test. The association clinicopathological variables outcome was studied by binary logistic regression analysis Cox...
Abstract Background The combination of the dual HER1/HER2 inhibitor lapatinib (L) and capecitabine (C) is a therapeutic option for patients (pts) with HER2+MBC whose disease progresses after treatment monoclonal antibody trastuzumab. At present time, no clinical or pathological factors except HER2 status are clearly recognized as predictors activity LC. We conducted retrospective analysis pts HER2-positive metastatic breast cancer receiving LC trastuzumab failure to identify associated...